Lundbeck Antipsychotic Sertindole Suspended From U.K. Market
Executive Summary
Lundbeck's antipsychotic sertindole has been suspended from the U.K. market "due to concerns about reports of cardiac arrhythmias and sudden cardiac arrest," the U.K. Committee for the Safety of Medicines told prescribers Dec. 2.
You may also be interested in...
Support For Serdolect In Specific Patients, But Panel Can’t Define Population
The only way Lundbeck's schizophrenia drug might make it to market is if the sponsor and FDA can find a population where the benefits merit the cardiovascular risk and come up with a way to manage that risk. But it's more complicated than meets the eye, and not necessarily something a Risk Evaluation and Mitigation Strategy can handle
Support For Serdolect In Specific Patients, But Panel Can’t Define Population
The only way Lundbeck's schizophrenia drug might make it to market is if the sponsor and FDA can find a population where the benefits merit the cardiovascular risk and come up with a way to manage that risk. But it's more complicated than meets the eye, and not necessarily something a Risk Evaluation and Mitigation Strategy can handle
Lundbeck Serlect NDA Revival Is One Project For CEO-Elect Braestrup
Lundbeck CEO-elect Claus Braestrup will oversee the company's renewed attempt to launch the antipsychotic Serlect (sertindole) in the U.S. when he assumes leadership of the Danish company in November